Choriocarcinoma is a very rare germinal testicular tumour and in literature its incidence has been reported to be 0.3% of all germinal testicular tumours. An important tumour marker is serum beta-hCG which not only helps in establishing diagnosis but also in assessing response to chemotherapy. In this study we present a case of testicular choriocarcinoma, who presented with abdominal pain, cough, generalized weakness and left sided cervical mass. Incisional biopsy of cervical mass was performed. Histopathology revealed metastatic choriocarcinoma. Serum beta-hCG levels were 1227 ng/mL. Patient received intravenous cycles of PEB (cisPlatin, Etoposide, Bleomycin) chemotherapy but he had progressive disease both radiologically and on tumour marker monitoring. He was planned for salvage chemotherapy but was lost to follow up there after. It is concluded that in males, choriocarcinoma carries a very dismal prognosis and a very poor response to chemotherapy and radiotherapy; surgery has no role in the management.

Download full-text PDF

Source

Publication Analysis

Top Keywords

testicular choriocarcinoma
8
germinal testicular
8
tumour marker
8
serum beta-hcg
8
response chemotherapy
8
cervical mass
8
testicular
4
choriocarcinoma diagnosed
4
diagnosed cervical
4
cervical lymph
4

Similar Publications

A 26-year-old male presented to a hospital with complaints of hemoptysis and right scrotal swelling. Computed tomography (CT) revealed right testicular swelling, multiple lung metastases, and small intestinal wall thickening. The patient's β-human chorionic gonadotropin, alpha-fetoprotein, lactate dehydrogenase, and hemoglobin levels were 103.

View Article and Find Full Text PDF
Article Synopsis
  • Germ cell tumors (GCTs), particularly choriocarcinoma, show differing characteristics and treatment outcomes based on their location, with testicular choriocarcinoma being more common and showing better survival rates than nontesticular forms.
  • The study analyzed data from 363 patients diagnosed between 2000 and 2018, finding that 74.4% had testicular choriocarcinoma, with surgery being a common treatment for these patients, especially among white individuals.
  • The results suggest the importance of tailored treatment approaches for different choriocarcinoma subtypes, highlight racial disparities in incidence, and indicate that while surgery improves outcomes, the role of chemotherapy and radiotherapy in
View Article and Find Full Text PDF

Human chorionic gonadotropin (hCG) has structural similarities with thyroid-stimulating hormone (TSH) and may stimulate TSH receptors at higher concentrations. During pregnancy, placental hCG causes TSH suppression, contributing to hyperemesis. However, in males, clinical manifestations caused by excess hCG are rare.

View Article and Find Full Text PDF

Background: Choriocarcinoma (CC) is a rare and aggressive form of germ cell tumor. There is limited evidence describing clinical outcomes in patients with primary CC and brain metastases (BM). Only a few single case reports have documented the use of stereotactic radiosurgery (SRS) for CC BM.

View Article and Find Full Text PDF
Article Synopsis
  • Epithelioid trophoblastic tumor (ETT) is a rare type of tumor found in the testis, with only seven cases documented before this study, which adds five more cases from a single institution, making it the largest series reported.
  • The patients had a mean age of 44, and most had prior testicular germ cell tumors treated with chemotherapy; ETT appeared in metastatic sites many years later, and its diagnosis was often associated with unusual histological features that can resemble other types of cancer.
  • Despite treatment, the outcomes were poor, with two patients dying within 17 months of diagnosis and three others remaining alive with metastatic disease averaging 20 months post-diagnosis, highlighting the aggressive nature of ETT.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!